Caspase-3 Colorimetric Assay Kit (TBS2030)
$289.00
Apoptosis plays a fundamental role in many normal biological processes as well as in several disease states. Apoptosis can be induced by various stimuli that all produce the same end result: systematic and orderly cell death. Caspases cleave a variety of cellular substrates after aspartic acid residues—a characteristic that is central to their role in mammalian apoptosis.
SKU | Stock | SIZE (test) | Price | Quantity | ||
---|---|---|---|---|---|---|
TBS2030 | Yes | 100 Tests | $289.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Apoptosis plays a fundamental role in many normal biological processes as well as in several disease states. Apoptosis can be induced by various stimuli that all produce the same end result: systematic and orderly cell death. Caspases cleave a variety of cellular substrates after aspartic acid residues—a characteristic that is central to their role in mammalian apoptosis. Caspases are synthesized in the cytosol of mammalian cells as inactive zymogens, which become active through intracellular caspase cascades.
The Tribo Caspase-3 Colorimetric Assay Kits provide a simple and convenient means for assaying the activity of caspases that recognize the sequence DEVD. The assay is based on spectrophotometric detection of the chromophore pnitroaniline (pNA) after cleavage from the labeled substrate DEVD-pNA. The pNA light emission can be quantified using a spectrophotometer or a microtiter plate reader at 400- or 405-nm. Comparison of the absorbance of pNA from an apoptotic sample with an uninduced control allows determination of the fold increase in caspase-3 activity.
Method
- Colorimetric
Storage Conditions
Store Cell Lysis buffer and Assay buffer at 4℃, Store all other components at -20℃. Shelf life of six months.
Additional information
SIZE (test) | 100 Tests |
---|
Be the first to review “Caspase-3 Colorimetric Assay Kit (TBS2030)”
You must be logged in to post a review.
Reviews
There are no reviews yet.